The pharmacokinetics of epirubicin

W. J F Van Der Vijgh, H. Weenen, S. E J M Van Der Poort, A. P R M Osterop, H. M. Pinedo, J. G. McVie

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of epirubicin was studied in patients with soft tissue sarcomas or advanced breast cancer. The epirubicin was given as an i.v. bolus injection of 75 or 90 mg/m2. Blood and urine samples were collected at regular time intervals for at least 48 hours. Extraction and high performance liquid chromatography of the samples were done. It was found that epirubicin compared to doxorubicin has a unique glucuronidation pathway which may explain its shorter half-life and its reduced cardiotoxicity.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalClinical Trials Journal
Issue numberSUPPL. 1
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'The pharmacokinetics of epirubicin'. Together they form a unique fingerprint.

Cite this